Month: February 2023

External evaluation of risperidone population pharmacokinetic models using opportunistic pediatric data was written by Karatza, Eleni;Ganguly, Samit;Hornik, Chi D.;Muller, William J.;Al-Uzri, Amira;James, Laura;Balevic, Stephen J.;Gonzalez, Daniel. And the article was included in Frontiers in Pharmacology in 2022.Application In Synthesis of 3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one This article mentions the following:

Risperidone is approved to treat schizophrenia in adolescents and autistic disorder and bipolar mania in children and adolescents. It is also used off-label in younger children for various psychiatric disorders. Several population pharmacokinetic models of risperidone and 9-OH-risperidone have been published. The objectives of this study were to assess whether opportunistically collected pediatric data can be used to evaluate risperidone population pharmacokinetic models externally and to identify a robust model for precision dosing in children. A total of 103 concentrations of risperidone and 112 concentrations of 9-OH-risperidone, collected from 62 pediatric patients (0.16-16.8 years of age), were used in the present study. The predictive performance of five published population pharmacokinetic models (four joint parent-metabolite models and one parent only) was assessed for accuracy and precision of the predictions using statistical criteria, goodness of fit plots, prediction-corrected visual predictive checks (pcVPCs), and normalized prediction distribution errors (NPDEs). The tested models produced similarly precise predictions (Root Mean Square Error [RMSE]) ranging from 0.021 to 0.027 nmol/mL for risperidone and 0.053-0.065 nmol/mL for 9-OH-risperidone). However, one of the models (a one-compartment mixture model with clearance estimated for three subpopulations) developed with a rich dataset presented fewer biases (Mean Percent Error [MPE, %] of 1.0% vs. 101.4, 146.9, 260.4, and 292.4%) for risperidone. In contrast, a model developed with fewer data and a more similar population to the one used for the external evaluation presented fewer biases for 9-OH-risperidone (MPE: 17% vs. 69.9, 47.8, and 82.9%). None of the models evaluated seemed to be generalizable to the population used in this anal. All the models had a modest predictive performance, potentially suggesting that sources of inter-individual variability were not entirely captured and that opportunistic data from a highly heterogeneous population are likely not the most appropriate data to evaluate risperidone models externally. In the experiment, the researchers used many compounds, for example, 3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (cas: 144598-75-4Application In Synthesis of 3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one).

3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (cas: 144598-75-4) belongs to isoxazole derivatives. Isoxazole rings are found in some natural products, such as ibotenic acid and muscimol. The most common methods for N–O bond cleavage in isoxazoles are hydrogenation with palladium or platinum catalysts or with Raney Ni. Recent developments have shown that Mo(CO)6 efficiently cleaves the N–O bond in isoxazoles.Application In Synthesis of 3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

Brain glutamate concentration in men with early psychosis: a magnetic resonance spectroscopy case-control study at 7 T was written by Godlewska, Beata R.;Minichino, Amedeo;Emir, Uzay;Angelescu, Ilinca;Lennox, Belinda;Micunovic, Masa;Howes, Oliver;Cowen, Philip J.. And the article was included in Translational Psychiatry in 2021.Recommanded Product: 144598-75-4 This article mentions the following:

Abnormalities in glutamate neurotransmission are linked to psychotic symptoms and cognitive dysfunction in schizophrenia. magnetic resonance spectroscopy (MRS) provides an acceptable means of measuring glutamate in the human brain but findings from patient studies at conventional magnetic field strength show considerable heterogeneity. Ultra-high-field MRS offers greater precision in glutamate measurement, particularly in delineation of glutamate from its precursor and metabolite, glutamine. This study aimed to use high-field (7 T) MRS to measure concentrations of glutamate and glutamine in three brain regions, anterior cingulate cortex (ACC), dorsolateral prefrontal cortex (DLPFC) and putamen (PUT), in young men with early psychosis. MRS was performed in 17 male participants with early psychosis and 18 healthy age-matched controls. Neurometabolite levels were calculated with unsuppressed water signal as the reference and corrected for individual gray matter, white matter and cerebrospinal fluid concentration Cognitive function was measured with the Brief Assessment of Cognition in Schizophrenia (BACS). Compared to controls, patients with early psychosis had lower concentrations of glutamate and glutamine in ACC. No differences were apparent in the DLPFC and PUT. In patients with early psychosis, there was a highly significant correlation between glutamate concentration in ACC and performance on the BACS, though the numbers available for this anal. were small. Our finding of lower glutamate levels in ACC in patients with schizophrenia is consistent with a recent meta-anal. of 7 T studies and suggests that this abnormality is present in both patients with early psychosis and those with longer-established illness. The possible link between ACC glutamate and cognitive performance requires replication in larger studies. In the experiment, the researchers used many compounds, for example, 3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (cas: 144598-75-4Recommanded Product: 144598-75-4).

3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (cas: 144598-75-4) belongs to isoxazole derivatives. Isoxazoles are aromatic heterocycles containing an N–O bond. Isoxazoles are commonly used as enaminoketone or β-diketone surrogate. As with isoxazolines, isoxazoles may be cleaved using low-valent titanium obtained from the Kulinkovich reaction.This procedure affords enaminoketones from 2,4-substituted isoxazoles.Recommanded Product: 144598-75-4

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

Known drugs identified by structure-based virtual screening are able to bind sigma-1 receptor and increase growth of huntington disease patient-derived cells was written by Battista, Theo;Pascarella, Gianmarco;Staid, David Sasah;Colotti, Gianni;Rosati, Jessica;Fiorillo, Annarita;Casamassa, Alessia. And the article was included in International Journal of Molecular Sciences in 2021.Application In Synthesis of 3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one This article mentions the following:

Huntington disease (HD) is a devastating and presently untreatable neurodegenerative disease characterized by progressively disabling motor and mental manifestations. The sigma-1 receptor (σ1R) is a protein expressed in the central nervous system, whose 3D structure has been recently determined by X-ray crystallog. and whose agonists have been shown to have neuroprotective activity in neurodegenerative diseases. To identify therapeutic agents against HD, we have implemented a drug repositioning strategy consisting of: (i) Prediction of the ability of the FDA-approved drugs publicly available through the ZINC database to interact with s1R by virtual screening, followed by computational docking and visual examination of the 20 highest scoring drugs; and (ii) Assessment of the ability of the six drugs selected by computational analyses to directly bind purified s1R in vitro by Surface Plasmon Resonance and improve the growth of fibroblasts obtained from HD patients, which is significantly impaired with respect to control cells. All six of the selected drugs proved able to directly bind purified s1R in vitro and improve the growth of HD cells from both or one HD patient. These results support the validity of the drug repositioning procedure implemented herein for the identification of new therapeutic tools against HD. In the experiment, the researchers used many compounds, for example, 3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (cas: 144598-75-4Application In Synthesis of 3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one).

3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (cas: 144598-75-4) belongs to isoxazole derivatives. An isoxazolyl group is found in many beta-lactamase-resistant antibiotics, such as cloxacillin, dicloxacillin and flucloxacillin. As with isoxazolines, isoxazoles may be cleaved using low-valent titanium obtained from the Kulinkovich reaction.This procedure affords enaminoketones from 2,4-substituted isoxazoles.Application In Synthesis of 3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

Evaluation of carcinogenicity studies of medicinal products for human use authorised via the European centralised procedure (1995-2009) was written by Friedrich, Anita;Olejniczak, Klaus. And the article was included in Regulatory Toxicology and Pharmacology in 2011.Application of 210421-74-2 This article mentions the following:

Carcinogenicity data of medicinal products for human use that have been authorized via the European centralized procedure (CP) between 1995 and 2009 were evaluated. Carcinogenicity data, either from long-term rodent carcinogenicity studies, transgenic mouse studies or repeat-dose toxicity studies were available for 144 active substances contained in 159 medicinal products. Out of these compounds, 94 (65%) were pos. in at least one long-term carcinogenicity study or in repeat-dose toxicity studies. Fifty compounds (35%) showed no evidence of a carcinogenic potential. Out of the 94 compounds with pos. findings in either carcinogenicity or repeat-dose toxicity studies, 33 were pos. in both mice and rats, 40 were pos. in rats only, and 21 were pos. exclusively in mice. Long-term carcinogenicity studies in two rodent species were available for 116 compounds Data from one long-term carcinogenicity study in rats and a transgenic mouse model were available for eight compounds For 13 compounds, carcinogenicity data were generated in only one rodent species. One compound was exclusively tested in a transgenic mouse model. Six compounds were tumorigenic in repeat-dose toxicity studies in rats. The majority of tumor findings observed in rodent carcinogenicity studies were considered not to be relevant for humans, either due to a rodent-specific mechanism of carcinogenicity, a high safety margin between exposures at the NOAEL (No Observed Adverse Effect Level) in rodents and recommended therapeutic doses in humans, or based on historical control data, a small effect size and lack of dose-response relationship and tumors typically observed in rodent strains used, or were considered not to be relevant for humans based on literature and clin. data or likely differences in metabolism/local concentrations between rodents and humans. Due to the high number of rodent tumor findings with unlikely relevance for humans, the value of the currently used testing strategy for carcinogenicity appears questionable. A revision of the carcinogenicity testing paradigm is warranted. In the experiment, the researchers used many compounds, for example, Sodium (4-chloro-3-methylisoxazol-5-yl)((2-(2-(6-methylbenzo[d][1,3]dioxol-5-yl)acetyl)thiophen-3-yl)sulfonyl)amide (cas: 210421-74-2Application of 210421-74-2).

Sodium (4-chloro-3-methylisoxazol-5-yl)((2-(2-(6-methylbenzo[d][1,3]dioxol-5-yl)acetyl)thiophen-3-yl)sulfonyl)amide (cas: 210421-74-2) belongs to isoxazole derivatives.Synthetically, isoxazoles serve as valuable precursors for the construction of diverse molecules, including many natural products. Fe(CO)5 efficiently cleaves the N–O bond of fused isoxazolo-1,4-quinones to give the corresponding imines.All the common reducing reagents failed to open the isoxazole ring.Application of 210421-74-2

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

Proton spin-spin coupling constants in isothiazole, isoxazole, and some of their alkyl derivatives was written by Wasylishen, Roderick E.;Rowbotham, J. Brian;Schaefer, Ted. And the article was included in Canadian Journal of Chemistry in 1974.Computed Properties of C4H5NO This article mentions the following:

The signs and magnitudes of the spin-spin coupling constants over three to six bonds between protons in isothiazole, isoxazole, and in 10 of their alkyl derivatives are discussed in terms of the coupling mechanisms. The chem. shifts of ring protons and Me protons arise from a common mechanism originating in the ring but are not simply related to electron ds. calculated by MO theory at the CNDO/2 level of approximation In the experiment, the researchers used many compounds, for example, 5-Methylisoxazole (cas: 5765-44-6Computed Properties of C4H5NO).

5-Methylisoxazole (cas: 5765-44-6) belongs to isoxazole derivatives. Isoxazoles are aromatic heterocycles containing an N–O bond. The weakness of this bond allows the ring opening of these heterocycles under reductive conditions. Isoxazole can be synthesised via a variety of methods. Examples include via a 1,3-dipolar cycloaddition of nitrile oxides with alkynes.Computed Properties of C4H5NO

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

Relationship between CYP2D6 genotype, activity score and phenotype in a pediatric Thai population treated with risperidone was written by Hongkaew, Yaowaluck;Gaedigk, Andrea;Wilffert, Bob;Ngamsamut, Nattawat;Kittitharaphan, Wiranpat;Limsila, Penkhae;Sukasem, Chonlaphat. And the article was included in Scientific Reports in 2021.Formula: C23H27FN4O3 This article mentions the following:

Recently, the Clin. Pharmacogenetics Implementation Consortium (CPIC) have revised recommendations for the translation of CYP2D6 genotype to phenotype. Changes affect phenotype grouping, as well as the value used to calculate activity score for the CYP2D6*10 allele to better reflect the substantially decreased activity of this allele which is the most frequent allele found in Asian populations. This study aimed to evaluate whether the lower value for CYP2D6*10 as recommended, and the revised phenotype groupings improve the relationship between CYP2D6 genotype and risperidone measures. One hundred and ninety-nine children and adolescents with autism treated with a risperidone-based regimen for at least four weeks were included. CYP2D6 genotype was determined using the Luminex xTAG CYP2D6 Kit assay and translated into phenotype using different translation methods. Plasma concentrations of risperidone and 9-hydroxyrisperidone were measured using LC/MS/MS. Plasma levels of risperidone, risperidone concentration/dose ratio, and risperidone/9-hydroxyrisperidone ratio in patients with an activity score < 1 were significantly higher than those ≥ 1 (P value < 0.001 for all three parameters). Plasma risperidone levels and risperidone concentration/dose ratios were significantly higher in intermediate metabolizers (defined as AS = 0.25-0.75) than normal metabolizer (defined as AS = 1-2) patients (1.44 vs. 0.23 ng/mL, P < 0.001 and 1.63 vs. 0.29 ng/mL/ng, P < 0.001, resp.) as well as risperidone/9-hydroxyrisperidone ratio (0.20 vs. 0.04, P < 0.001). This is the first study in an Asian population utilizing the revised CPIC-recommended method for translating the CYP2D6 genotype to phenotype. In addition to validating that CYP2D6 genetic variation significantly impacts risperidone metabolism, we demonstrated that revised value for the CYP2D6*10 was superior for genotype to phenotype translation. However, at least for risperidone, subjects with an activity score of 1 presented as phenotypic normal, and not intermediate metabolizers, suggesting that phenotype classification is substrate dependent. In the experiment, the researchers used many compounds, for example, 3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (cas: 144598-75-4Formula: C23H27FN4O3).

3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (cas: 144598-75-4) belongs to isoxazole derivatives. Isoxazoles are aromatic heterocycles containing an N–O bond. The weakness of this bond allows the ring opening of these heterocycles under reductive conditions. Isoxazole can be synthesised via a variety of methods. Examples include via a 1,3-dipolar cycloaddition of nitrile oxides with alkynes.Formula: C23H27FN4O3

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

Paliperidone Extended Release Versus Olanzapine in Treatment-Resistant Schizophrenia: A Randomized, Double-Blind, Multicenter Study was written by Wang, Dandan;Wei, Ning;Hu, Fangzhen;Li, Jianhua;Wang, Yucheng;Qian, Zhiwei;Yang, Miao;Yao, Mingrong;Xia, Yong;Yu, Hong;Tu, Wenzhen;Ye, Minjie;Qian, Cheng;Hu, Jianbo;Chen, Jingkai;Hu, Chanchan;Huang, Manli;Xu, Yi;Hu, Shaohua. And the article was included in Journal of Clinical Psychopharmacology in 2022.Application In Synthesis of 3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one This article mentions the following:

Paliperidone is an atypical antipsychotic as effective as other atypical antipsychotics for schizophrenia. However, few studies have explored the efficacy of paliperidone for treatment-resistant schizophrenia. This study aimed to compare the efficacy and safety of paliperidone extended release (ER) vs. olanzapine in schizophrenia patients with either poor treatment response or intolerable adverse effects due to standardized antipsychotic therapy. This 12-wk randomized, double-blind, multicenter study compared the treatment efficacy on psychotic symptoms, cognitive functions, and tolerance between paliperidone ER (6-15 mg/d, n = 45) and olanzapine (10-30 mg/d, n = 41) in treatment-resistant or treatment-intolerant patients with schizophrenia. The severity of psychotic symptoms was evaluated by the Pos. and Neg. Syndrome Scale and the Clin. Global Impression Severity of Illness Scale. The cognitive functions were assessed by the MATRICS Consensus Cognitive Battery. In addition, the metabolic impacts were evaluated by weight gain and waist circumference. Patients with either paliperidone ER or olanzapine treatment showed apparent improvement in psychotic symptoms, without significant intergroup difference. Twelve-week paliperidone ER or olanzapine treatment did not improve the cognitive functions. Both paliperidone ER and olanzapine treatment caused significant increase in weight and waist circumference, and olanzapine had a greater impact on waist circumference than paliperidone ER. In addition, both drugs were well tolerated. Paliperidone ER could be a safe alternative for treatment-resistant schizophrenia. In the experiment, the researchers used many compounds, for example, 3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (cas: 144598-75-4Application In Synthesis of 3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one).

3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (cas: 144598-75-4) belongs to isoxazole derivatives. Isoxazoles are aromatic heterocycles containing an N–O bond. Isoxazoles are commonly used as enaminoketone or β-diketone surrogate. Some alternative routes for the synthesis of isoxazoles have also been developed and reported. The 2-benzoyl-2-halo-2H-azirines provide 4-haloisoxazoles in good yields after heating in toluene at reflux temperature.Application In Synthesis of 3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

Preparation of β-oxo nitriles through acylation of trimethylsilyl cyanoacetate by mixed anhydrides was written by Goasdoue, Claude;Couffignal, Rene. And the article was included in Tetrahedron Letters in 1979.SDS of cas: 5765-44-6 This article mentions the following:

Treating Me₃SiO₂CCHLiCN (I) and EtCHLiCN with RCO₂CO₂Et (R = Pr, Ph) gave 59 and 74% RCOCH₂CN, and 55 and 74% RCOCHEtCN, resp. I was prepared by treating HO₂CCH₂CN with Me₃SiCl (90%) followed by lithiation. In the experiment, the researchers used many compounds, for example, 5-Methylisoxazole (cas: 5765-44-6SDS of cas: 5765-44-6).

5-Methylisoxazole (cas: 5765-44-6) belongs to isoxazole derivatives. Isoxazole are described as inhibitors of acetylcholinesterase (AChE). Isoxazole ligands bind to and inhibit the Sxc- antiporter. Isoxazoles are potent isosteres of pyridine and have been found to inhibit voltage-gated sodium channels for pain control, for the construction of tetracycline antibiotic derivatives, and as a therapeutic agent for depression.SDS of cas: 5765-44-6

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

Development of antiinflammatory agents. I. Isoxazole derivatives was written by Park, No Sang;Kim, Hyun Sook;Min, Changhee;Choi, Joong Kwon. And the article was included in Yakhak Hoechi in 1990.Application In Synthesis of 3-(Trifluoromethyl)isoxazol-5-amine This article mentions the following:

3-Substituted 5-aminoisoxazole-4-carboxylates I (R = CF₃, CHF₂, Ph, 4-MeOC₆H₄, 2-, 3-, or 4-R¹C₆H₄; R¹ = F, Cl, CF₃, NO₂; R² = Me) were prepared by the reaction of corresponding bromoaldoximes with cyanoacetate. I (R = CF₃, R² = Me) (II) was acylated with various aminopyridine derivatives to afford diamides. The ester group of II was hydrolyzed and decarboxylated easily to give 3-trifluoromethyl-5-aminoisoxazole. The aminoisooxazole was also converted to amides. The synthesized compounds were tested for antiinflammatory activities. In the experiment, the researchers used many compounds, for example, 3-(Trifluoromethyl)isoxazol-5-amine (cas: 108655-63-6Application In Synthesis of 3-(Trifluoromethyl)isoxazol-5-amine).

3-(Trifluoromethyl)isoxazol-5-amine (cas: 108655-63-6) belongs to isoxazole derivatives. Isoxazoles present in various natural products and synthetic compounds of biological importance like antibacterial, antagonists, antiinflammatory, analgesics, and also show the applications in functional materials. The electrophilic cyclization of various 2-alkynone O-methyl oximes with a wide range of substrates such as ICl, I2, Br2, PhSeBr, etc. provides a variety of 3,4,5-trisubstituted isoxazoles in good to excellent yields.Application In Synthesis of 3-(Trifluoromethyl)isoxazol-5-amine

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

Acetylenic compounds, XLIV. Synthesis of 3-aminoisoxazoles and 3-hydroxyisoxazoles (3-isoxazolones) was written by Iwai, Issei;Nakamura, Norio. And the article was included in Chemical & Pharmaceutical Bulletin in 1966.Recommanded Product: 14678-05-8 This article mentions the following:

A solution of β,4-dibromocinnamonitrile (0.0028 mole) in 10 ml. EtOH was mixed with NH2OH.HCl (0.016 mole) in 10 ml. 10% NaOH. After standing overnight, the mixture was extracted with ether. The ethereal layer was extracted with 10% HCl solution After neutralization with aqueous NaOH, yellow precipitate was taken up in ether. After evaporation of the solvent, the residue was crystallized from aqueous MeOH to yield 57% yellow 3-amino-5-(p-bromophenyl)isoxazole (I), m. 147-9°. To a solution of 12.2 g. ClCN in 150 ml. absolute ether was added a solution of Grignard reagent prepared from p-methoxyphenylpropiolonitrile (II), m. 78.5-80°. To a mixture of 0.018 mole NH2OH.HCl and 0.062 mole 10% NaOH was added a solution of 0.006 mole (II) in 25 ml. EtOH. After standing overnight the mixture was extracted with ether to give 41% 3-amino-5-(p-methoxyphenyl)isoxazole (III), m. 171-2°. Similarly prepared was 3-methyl-5-aminoisoxazole (IV) m. 84-5°, 3:1 mixture of 3-amino-5-phenylisoxazole and IV, 3-sulfanilamido-5-methylisoxazole, m. 166-7°, 5-aminoisoxazole, m. 75-7°, 5-benzamidoisoxazole, m. 134-5° (62% yield), 3 aminoisoxazole, b. 75-6°, 3-benzamidoisoxazole, m. 148-9°, 3-acetylsulfanilamidoisoxazole, m. 245-7° (decomposition), 3-sulfanilamidoisoxazole, m. 124-6°, 3-hydroxy-5-phenylisoxazole, m. 163-5°, 3-hydroxy-5-(p-nitrophenyl)isoxazole, m. 232-4° (decomposition), 3-hydroxy-5-(p-chlorophenyl)isoxazole, m. 220-1° (decomposition), 3-hydroxy-5-(p-methoxyphenyl)isoxazole, m. 212-14° (decomposition), 3-hydroxy-5-methylisoxazole, m. 84-5°, 3-hydroxyisoxazole, m. 98-9°, 3-phenyl-5-isoxazolone, m. 151-2°. In the experiment, the researchers used many compounds, for example, Isoxazol-5-amine (cas: 14678-05-8Recommanded Product: 14678-05-8).

Isoxazol-5-amine (cas: 14678-05-8) belongs to isoxazole derivatives. Isoxazoles present in various natural products and synthetic compounds of biological importance like antibacterial, antagonists, antiinflammatory, analgesics, and also show the applications in functional materials. Some alternative routes for the synthesis of isoxazoles have also been developed and reported. The 2-benzoyl-2-halo-2H-azirines provide 4-haloisoxazoles in good yields after heating in toluene at reflux temperature.Recommanded Product: 14678-05-8

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem